Single Dose Study of MK-2214 in Healthy Japanese Participants

A Single Dose Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetics of MK-2214 in Healthy Japanese Participants

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2031220627

Enrollment

Registered

2023-02-09

Start date

2023-03-17

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alzheimer's Disease

Interventions

Single i.v. dosing Panel A: MK-2214 700mg or Placebo Panel B: MK-2214 2100mg or Placebo Panel C and D: MK-2214 4200mg or Placebo

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Healthy male or female aged 18 to 75 years old with BMI 18 to 30 kg/m2

Exclusion criteria

Exclusion criteria: Has a history of clinically significant abnormalities or diseases

Design outcomes

Primary

Measure	Time frame
Adverse event	—

Secondary

Measure	Time frame
AUC0-inf, AUC0-last, AUC0-140d, AUC0-28d, Cmax, Tmax, t1/2, CL and Vz	—

Contacts

Public ContactMSDJRCT inquiry mailbox

MSD K.K.

msdjrct@msd.com+81-3-6272-1957

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026